March 25, 2020
On March 23, FDA updated its FAQ regarding specimen collection for COVID-19 testing. Based on the clinical data available, FDA believes that, for symptomatic patients, nasal swabs could be used that access just the front of the nose rather than the depth of the nasal cavity. This change would allow for specimen collection that is more comfortable for the patients, could enable self-collection of the specimen at the collection site, and could be performed with a type of swab that is more readily available, addressing supply concerns.
FDA also continues to issue additional Emergency Use Authorizations for diagnostic tests for COVID-19. As of the morning of March 25, thirteen tests now have received EUAs. Under its laboratory developed test policy for COVID-19, the FDA has been notified by 65 laboratories with tests.